← 產業報告目錄
Psoriasis Biosimilars Market Size, Share & Trends Analysis Report By Drug Class (TNF-alpha inhibitors (Infliximab, Etanercept, Adalimumab), Other biosimilars), By Route of Administration (Subcutaneous, Intravenous, Oral, Topical), By Indication (Plaque psoriasis, Psoriatic arthritis, Other types), By Distribution Channel, By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-01頁數 160報告編號 INSIGHTACE-1757c7da9b
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2023 valuation of USD 8.5 billion, the global Psoriasis Biosimilars Market is poised to advance to USD 19.3 billion by 2031, demonstrating a CAGR of 10.9% during the 2024–2031 forecast window.
The Psoriasis Biosimilars sector involves are economically viable substitutes for original biologics employed in the management of moderate to severe psoriasis. This domain has witnessed considerable transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is driven by mounting appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, driven by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Psoriasis Biosimilars Market Snapshot
Chapter 4. Global Psoriasis Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Psoriasis Biosimilars Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Psoriasis Biosimilars Industry Trends
Chapter 5. Psoriasis Biosimilars Market Segmentation 1: By Drug Class, Estimates & Trend Analysis
5.1. Market Share by Drug Class, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Class:
5.2.1. TNF-alpha Inhibitors
5.2.1.1. Infliximab
5.2.1.2. Etanercept
5.2.1.3. Adalimumab
5.2.2. Other Biosimilars
Chapter 6. Psoriasis Biosimilars Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Indications:
6.2.1. Plaque Psoriasis
6.2.2. Psoriatic Arthritis
6.2.3. Other Types
Chapter 7. Psoriasis Biosimilars Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administrations:
7.2.1. Subcutaneous
7.2.2. Intravenous
Chapter 8. Psoriasis Biosimilars Market Segmentation 4: By Sales Channel, Estimates & Trend Analysis
8.1. Market Share by Sales Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Sales Channels:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacy Chains
8.2.3. Online Pharmacies
Chapter 9. Psoriasis Biosimilars Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Psoriasis Biosimilars Market, Regional Snapshot 2023 & 2031
9.2. North America
9.2.1. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.2.3. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.2.4. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.2.5. North America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.3. Europe
9.3.1. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.3.3. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.3.4. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.3.5. Europe Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.4. Asia Pacific
9.4.1. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.4.3. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.4.4. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.4.5. Asia Pacific Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.5. Latin America
9.5.1. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.5.3. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.5.4. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.5.5. Latin America Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
9.6. Middle East & Africa
9.6.1. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.6.3. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2024-2031
9.6.4. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.6.5. Middle East & Africa Psoriasis Biosimilars Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Alvotech
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial PerDrug Classance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Amgen Inc.
10.2.3. Biocon
10.2.4. Biogen
10.2.5. Biosimilar Collaborations Ireland Limited
10.2.6. Boeheringer Ingelheim
10.2.7. Celltrion
10.2.8. Cipla
10.2.9. Coherus Biosciences
10.2.10. Cordavis Ltd.
10.2.11. Epirus Biopharmaceuticals
10.2.12. Fresenius Kabi
10.2.13. Glenmark Pharmaceuticals
10.2.14. Hanwha Chemical
10.2.15. Hetero
10.2.16. Innovent Biologics
10.2.17. Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
10.2.18. LG Chem
10.2.19. Lupin
10.2.20. Mabpharm
10.2.21. Merck
10.2.22. Mylan
10.2.23. Nichi-Iko Pharmaceutical
10.2.24. Organon & Co.
10.2.25. Pfizer
10.2.26. Ranbaxy Laboratories (now Sun Pharma)
10.2.27. Samsung Bioepis
10.2.28. Sandoz
10.2.29. Shanghai CP Guojian Pharmaceutical
10.2.30. Sorrento Therapeutics (partner)
10.2.31. Stada Arzneimittel AG
10.2.32. Sunshine Guojian Pharmaceutical
10.2.33. Synermore
10.2.34. Teva
10.2.35. Torrent Pharmaceuticals
10.2.36. YL Biologics
10.2.37. Zydus Cadila
10.2.38. Other prominent players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們